Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer

Shaodong Hong; Fangfang Gao; Sha Fu; Yan Wang; Wenfeng Fang; Yan Huang; Li Zhang

doi:10.1001/jamaoncol.2018.0049

Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer

JAMA Oncol. 2018 May 1;4(5):739-742. doi: 10.1001/jamaoncol.2018.0049.

Authors

Shaodong Hong^{1

2

3}, Fangfang Gao^{1

2

3}, Sha Fu⁴, Yan Wang⁵, Wenfeng Fang^{1

2

3}, Yan Huang^{1

2

3}, Li Zhang^{1

2

3}

Affiliations

¹ State Key Laboratory of Oncology in South China, Guangzhou.
² Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
³ Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
⁴ Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Pathology Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
⁵ Quest Genomics, Nanjing, China.

Abstract

This cohort study examines the association of concomitant genetics alterations with response to treatment with epidermal growth factor receptor tyrosine kinase inhibitors among patients with EGFR-mutant advanced non–small cell lung cancer.

Publication types

Letter

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / diagnosis
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics*
Circulating Tumor DNA
ErbB Receptors / genetics
Exons
Humans
Lung Neoplasms / diagnosis
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics*
Mutation*
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*

Substances

Antineoplastic Agents
Circulating Tumor DNA
Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors